On Thursday, BioScrip announced that it will buy offsite pharmacy company HomeChoice Partners from its parent company, DaVita HealthCare Partners , for $70 million cash. The terms of the deal include a standard "earn-out" clause, whereby acceptable economic performance by HomeChoice post-buyout obligates BioScrip to pay some unspecified sum to DaVita, in addition to the base purchase price.
BioScrip noted that one attraction of the deal is that BioScrip has accrued losses on its income statement, and brings with it a "future tax benefit" that BioScrip will be able to make use of. This tax loss carryforward is estimated to be worth $3.9 million.
Shares of BioScrip are up 2.2% on the news. Shares of DaVita are down 0.2%.
The article BioScrip Buys DaVita Subsidiary for $70 Million originally appeared on Fool.com.
Fool contributor Rich Smith has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.